Aug. 31 (UPI) --A third COVID-19 vaccine will be available shortly as Novavax joins Pfizer/BioNTech and Moderna in targeting variants that are now circulating. The U.S. Food and Drug ...

PLAY. FIVE ON YOUR HEALTH TONIGHT. THE FDA APPROVING NEW COVID 19 VACCINES FOR THIS FALL. BUT EXPERTS SAY SOME AMERICANS CAN STILL SAFELY WAIT TO GET ONE. JOINING US TO EXPLAIN ALL OF THIS IS ...

BioNTech's antibody-drug conjugate partner, DualityBio, has filed for a Hong Kong IPO. UCB will offload some Chinese assets for $680 million. And more. 1. Sanofi halts flu vaccine distribution in ...

The BNT116 vaccine, which has been developed by the German biotechnology company BioNTech (Mainz, Germany) as an immunotherapy treatment for non-small-cell lung cancer (NSCLC), uses mRNA to provide ...

Along the way, Duality has entered into deals with BioNTech, BeiGene and Adcendo that could be worth more than $4 billion. Duality plans to take two bispecific ADCs and one autoimmune ADC into ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...

Today, a brief rundown of news from Navigator Medicines and Merck & Co., as well as updates from Mubadala Investment Company and J&J that you may have missed. Merck & Co. has begun a second Phase 3 ...

(RTTNews) - Kuick Research announced the initiation of the first mRNA lung cancer vaccine trials globally with German biotech firm BioNTech SE's (BNTX) BNT116 as a significant breakthrough in ...

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC). The vaccine is claimed to use the ...

Credit: Kitsawet Saethao/Shutterstock. BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC).

This innovative project, featuring BioNTech’s BNT116, heralds the dawn of a transformative period in cancer therapy domain, with the potential to fundamentally change our strategies for cancer ...